Nothing said here yet.
to join the conversation.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at…
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Proactive's Stephen Gunnion after the company presented findings from its Long COVID and Parkinson’s disease trials at the American Neurological Association’s Annual Meeting in San Diego.
Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue, post-exertional malaise, and objective cognitive measures in Long COVID patients with higher baseline symptom burdenCARSON…
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson’s disease, at the American Neurological Association’s annual meeting in San Diego.
ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp.
BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could strengthen the case for targeting inflammation and insulin…
BioVie (NASDAQ:BIVI) shares fell nearly 9. 7% in premarket trading after the company reported results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms associated with Long COVID.
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S.
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc.